Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.5K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

574
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
574
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.3K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.2K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.2K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

830
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
830
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

512
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
512

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between locomotor muscle quality and cardiac function during exercise in heart failure with preserved ejection fraction.

European journal of heart failure·2024
Same author

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.

Journal of the American College of Cardiology·2024
Same author

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

The New England journal of medicine·2024
Same author

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.

Circulation·2024
Same author

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.

Nature medicine·2024
Same author

Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation.

JAMA cardiology·2024
Same journal

Implantable cardioverter-defibrillator in cardiac sarcoidosis: A propensity-score matched analysis.

Current problems in cardiology·2026
Same journal

Arterial Stiffness in Heart Failure with Preserved Ejection Fraction: is this a new Predisposing Factor?

Current problems in cardiology·2026
Same journal

The future of cardiovascular training: Bridging global disparities and building a hybrid model for equity in care.

Current problems in cardiology·2026
Same journal

Disparities in healthcare access and treatment outcomes for patients with chronic limb-threatening ischemia.

Current problems in cardiology·2026
Same journal

Diagnostic and prognostic value of coronary computed tomography angiography and high-risk plaque assessment in acute coronary syndrome.

Current problems in cardiology·2026
Same journal

Prognostic value of albuminuria in heart failure with preserved ejection fraction: A systematic review.

Current problems in cardiology·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K

Heart Failure With Preserved Ejection Fraction.

Yogesh N V Reddy, Barry A Borlaug

    Current Problems in Cardiology
    |March 9, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Heart failure with preserved ejection fraction (HFpEF) is a growing global health burden. Unlike heart failure with reduced ejection fraction (HFrEF), HFpEF lacks effective treatments, highlighting distinct pathophysiologies.

    More Related Videos

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
    07:09

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

    Published on: February 18, 2022

    2.5K
    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    03:42

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: March 29, 2024

    2.2K

    Related Experiment Videos

    Last Updated: Mar 24, 2026

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
    09:20

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

    Published on: February 13, 2021

    7.2K
    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
    07:09

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

    Published on: February 18, 2022

    2.5K
    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    03:42

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: March 29, 2024

    2.2K

    Area of Science:

    • Cardiology
    • Internal Medicine
    • Public Health

    Background:

    • Heart failure (HF) significantly impacts global morbidity and healthcare costs.
    • Heart failure with preserved ejection fraction (HFpEF) drives increasing HF prevalence, linked to obesity, hypertension, and metabolic syndrome.
    • Despite advances in heart failure with reduced ejection fraction (HFrEF) treatments, HFpEF outcomes remain unchanged, indicating fundamental differences.

    Purpose of the Study:

    • To review the current understanding of HFpEF pathophysiology.
    • To discuss diagnostic and therapeutic strategies for HFpEF.
    • To outline future research directions for HFpEF.

    Main Methods:

    • Literature review of current research on HFpEF.
    • Analysis of pathophysiological mechanisms specific to HFpEF.
    • Synthesis of diagnostic criteria and treatment approaches for HFpEF.

    Main Results:

    • HFpEF pathophysiology involves distinct mechanisms compared to HFrEF.
    • Current HFrEF therapies are largely ineffective for HFpEF.
    • Diagnostic challenges persist for HFpEF, necessitating further investigation.

    Conclusions:

    • HFpEF represents a distinct clinical entity requiring tailored management strategies.
    • Understanding HFpEF pathophysiology is crucial for developing effective therapies.
    • Future clinical investigations should focus on novel diagnostic and therapeutic targets for HFpEF.